Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: A randomized trial

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Duval, Xavier ^a,b   Caplanusi, Adrian ^c   Laurichesse, Henri ^d,e   Deplanque, Dominique ^f,g   Loulergue, Pierre ^h   Vaman, Tejaswini ⁱ   Launay, Odile ^a,h   Gillard, Paul ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICHAT HOSPITAL   (France)

^c GSK   (Belgium)

^d UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^e INRA and University of Auvergne   (France)

^f UNIV LILLE   (France)

^g INSERM   (France)

^h Institut Cochin   (France)

ⁱ GlaxoSmithCline Vaccines   (India)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BRONCHITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEMAGGLUTINATION INHIBITION; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; URTICARIA;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; TIME FACTORS; VACCINATION; YOUNG ADULT;

EID: 84871153572     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-162     Document Type: Article

References (30)

1. Nidom CA, Takano R, Yamada S, Sakai-Tagawa Y, Daulay S, Aswadi D, Suzuki T, Suzuki Y, Shinya K, Iwatsuki-Horimoto K, Muramoto Y, Kawaoka Y. Influenza A (H5N1) viruses from pigs, Indonesia. Emerg Infect Dis 2010, 16(10):1515-23. 10.3201/eid1610.100508, 3294999, 20875275.
2. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NJ. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR 2009, 58(RR-8):1-52.
3. Fedson DS, Dunhill P. Commentary: from scarcity to abundance: pandemic vaccines and other agents for 'have not' countries. J Public Health Policy 2007, 28:322-340. 10.1057/palgrave.jphp.3200147, 17717543.
4. Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster JM, Leroux-Roels G. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine. Lancet 2007, 370:580-89. 10.1016/S0140-6736(07)61297-5, 17707753.
5. Leroux-Roels I, Bernhard R, Gerard P, Dramé M, Hanon E, Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008, 3:e1665. 10.1371/journal.pone.0001665, 2253495, 18301743.
6. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, Pistoor FH, van Amerongen G, Wettendorff MA, Hanon E, Osterhaus AD. Crossprotection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008, 3:e1401. 10.1371/journal.pone.000140, 2151135, 18167560.
7. Rumke HC, Bayas JM, de Juanes JM, Caso C, Richardus JH, Campins M, Rombo L, Duval X, Romanenko V, Schwarz TF, Fassakhov R, Abad-Santos F, von Sonnenburg F, Dramé M, Sänger R, Ballou WR. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008, 26:2378-88. 10.1016/j.vaccine.2008.02.068, 18407382.
8. Chu DW, Hwang SJ, Lim FS, Lin Oh HM, Thongcharoen P, Yang PC, Bock HL, Dramé M, Gillard P, Hutagalung Y, Tang H, Teoh YL, Ballou RW, on behalf of the H5N1 Flu Study Group for Hong Kong, Singapore, Taiwan and Thailand Immunogenicity and tolerability of an AS03-adjuvanted prepandemic influenza vaccine. A phase III study in a large population of Asian adults. Vaccine 2009, 27:7428-35. 10.1016/j.vaccine.2009.07.102, 19683087, on behalf of the H5N1 Flu Study Group for Hong Kong, Singapore, Taiwan and Thailand.
9. EPAR product information: updated 27/02/2012 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000832/WC500038122.pdf.
10. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged up to 85 years. Clin Infect Dis 2010, 51(6):668-677. 10.1086/655830, 20687838.
11. Gillard P, Caplanusi A, Knuf M, Roman F, Walravens K, Moris P, Dramé M, Schwarz TF. An assessment of prime-boost vaccination schedules with AS03(A)-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Infl Other Resp Viruses 2012, Epub.
12. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361:2405-13. 10.1056/NEJMoa0907413, 19745216.
13. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-35. 10.1056/NEJMoa0907650, 19745215.
14. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375:41-8. 10.1016/S0140-6736(09)62026-2, 20018365.
15. Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010, 375:49-55. 10.1016/S0140-6736(09)62039-0, 20018367.
16. EPAR Product information: updated 14/06/2012 Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000710/WC500023756.pdf.
17. Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Mamadou Dramé M, Gillard P, Jilg W. Single dose vaccination with AS03-adjuvanted H5N1 vaccinesin a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009, 27:6284-90. 10.1016/j.vaccine.2009.01.040, 19856521.
18. Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended to be used outside of the core dossier context (EMEA/CHMP/VWP/263499/ 2006) 2007, European Agency for the Evaluation of Medicinal Products.
19. Availability of a candidate reassortant vaccine virus for the novel Influenza A (H1N1) vaccine development X-179A 2009, Accessed May 2011, at http://www.who.int/csr/resources/publications/swineflu/candidates_X-179a/en/.).
20. Hehme NW, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, Sänger R. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 2002, 22:751-69.
21. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Jeanne-Marie Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial. Vaccine 2010, 28:1740-45. 10.1016/j.vaccine.2009.12.014, 20034605.
22. Roman F, Clément F, Dewé W, Walravens K, Maes C, Willekens J, De Boever F, Hanon E, Leroux-Roels G. Effect on cellular and humoral immune responses of the AS03 Adjuvant System in an A/H1N1/2009 influenza vaccine administered to adults during two randomised controlled trials. Clin Vaccine Immunol 2011, 18:835-43. 10.1128/CVI.00480-10, 3122530, 21450978.
23. Deng Y, Jing Y, Campbell AE, Gravenstein S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 2004, 172:3437-46.
24. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24:1159-69. 10.1016/j.vaccine.2005.08.105, 16213065.
25. McElhaney JE, Dutz JP. Better influenza vaccines for older people: what will it take?. JID 2008, 198:632-4. 10.1086/590435, 18652548.
26. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007, 6:699-710. 10.1586/14760584.6.5.699, 17931151.
27. Heijmans S, De Meulemeester M, Reynders P, Giet D, Demanet E, Devresse PY, Icardi G, Dramé M, Roman F, Gillard P. Immunogenicity profile of a 3.75 μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in the elderly. J Infect Dis 2011, 203:1054-62. 10.1093/infdis/jiq174, 3068020, 21450995.
28. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, Brammer TL, Cox NJ, Tumpey TM, Katz JM. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361:1945-52. 10.1056/NEJMoa0906453, 19745214.
29. Skountzou I, Koutsonanos DG, Kim JH, Powers R, Satyabhama L, Masseoud F, Weldon WC, Martin Mdel P, Mittler RS, Compans R, Jacob J. Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus. J Immunol 2010, 185(3):1642-9. 10.4049/jimmunol.1000091, 20585035.
30. Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, Madariaga M, Fries L, Godeaux O, Vaughn D. Safety and Long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 Adjuvant. JID 2012, 205:733-744. 10.1093/infdis/jir641, 22315336.